Skip to main content

Making genuine progress against metastatic breast cancer.

Publication ,  Journal Article
Lyman, GH; Burstein, HJ; Buzdar, AU; D'Agostino, R; Ellis, PA
Published in: J Clin Oncol
October 1, 2012

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

October 1, 2012

Volume

30

Issue

28

Start / End Page

3448 / 3451

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Survival Rate
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Humans
  • Female
  • Endpoint Determination
  • Drug Approval
  • Disease-Free Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., Burstein, H. J., Buzdar, A. U., D’Agostino, R., & Ellis, P. A. (2012). Making genuine progress against metastatic breast cancer. J Clin Oncol, 30(28), 3448–3451. https://doi.org/10.1200/JCO.2012.43.6931
Lyman, Gary H., Harold J. Burstein, Aman U. Buzdar, Ralph D’Agostino, and Paul A. Ellis. “Making genuine progress against metastatic breast cancer.J Clin Oncol 30, no. 28 (October 1, 2012): 3448–51. https://doi.org/10.1200/JCO.2012.43.6931.
Lyman GH, Burstein HJ, Buzdar AU, D’Agostino R, Ellis PA. Making genuine progress against metastatic breast cancer. J Clin Oncol. 2012 Oct 1;30(28):3448–51.
Lyman, Gary H., et al. “Making genuine progress against metastatic breast cancer.J Clin Oncol, vol. 30, no. 28, Oct. 2012, pp. 3448–51. Pubmed, doi:10.1200/JCO.2012.43.6931.
Lyman GH, Burstein HJ, Buzdar AU, D’Agostino R, Ellis PA. Making genuine progress against metastatic breast cancer. J Clin Oncol. 2012 Oct 1;30(28):3448–3451.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

October 1, 2012

Volume

30

Issue

28

Start / End Page

3448 / 3451

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Survival Rate
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Humans
  • Female
  • Endpoint Determination
  • Drug Approval
  • Disease-Free Survival